U.S. Infectious Disease Molecular Diagnostics Market Size & Outlook
The infectious disease molecular diagnostics market in the United States is expected to reach a projected revenue of US$ 7,175.8 million by 2030. A compound annual growth rate of 3.6% is expected of the United States infectious disease molecular diagnostics market from 2025 to 2030.
Clinical Diagnostics
In Vitro Diagnostics
Infectious Disease Molecular Diagnostics Market Outlook
U.S. infectious disease molecular diagnostics market highlights
The U.S. infectious disease molecular diagnostics market generated a revenue of USD 5,807.2 million in 2024 and is expected to reach USD 7,175.8 million by 2030.
The U.S. market is expected to grow at a CAGR of 3.6% from 2025 to 2030.
In terms of segment, reagents product was the largest revenue generating product in 2024.
Others Product is the most lucrative product segment registering the fastest growth during the forecast period.
Infectious disease molecular diagnostics market data book summary
Abbott Laboratories, Danaher Corp, BioMerieux SA, Roche Holding AG ADR, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Becton Dickinson & Co, Hologic Inc, Illumina Inc, Grifols SA Ordinary Shares - Class A, Qiagen NV, Siemens Healthineers AG ADR, Sysmex Corp
Other key industry trends
In terms of revenue, U.S. accounted for 36.5% of the global infectious disease molecular diagnostics market in 2024.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
In North America, U.S. infectious disease molecular diagnostics market is projected to lead the regional market in terms of revenue in 2030.
U.S. is the fastest growing regional market in North America and is projected to reach USD 7,175.8 million by 2030.
The U.S. leads the molecular diagnostics market due to local presence of leading players, such as Roche Diagnostics, Abbott, and BD. One of the reasons for their continued dominance is presence of wellestablished R&D infrastructure and favorable reimbursement policies.
In addition, regulatory and reimbursement landscape is continuously evolving to adapt to the fast-paced research progress in this sector. Moreover, FDA is developing new regulatory strategies regarding NGS, which is anticipated to boost innovation in tests, while ensuring that the data produced by these tests are accurate and reliable.
The increase in number of COVID-19 cases is expected to aid launch of new products under the EUA, aiding growth. In March 2020, first EUA was granted to BioFire Respiratory Panel 2.1, which was followed by other products like PerkinElmer SARS-CoV-2 RT-qPCR Reagent Kit and BD SARS-CoV-2/Flu. Multidrug Resistant (MDR) bacteria are associated with nosocomial infections and are a threat to public health.
U.S. Infectious Disease Molecular Diagnostics Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Infectious Disease Molecular Diagnostics Market Outlook will help companies and investors design strategic landscapes.
Reagents Product was the largest segment with a revenue share of 67.67% in 2024.
Horizon Databook has segmented the U.S. infectious disease molecular diagnostics market based on instruments product, reagents product, others product covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. leads the molecular diagnostics market due to local presence of leading players, such as Roche Diagnostics, Abbott, and BD. One of the reasons for their continued dominance is presence of wellestablished R&D infrastructure and favorable reimbursement policies.
In addition, regulatory and reimbursement landscape is continuously evolving to adapt to the fast-paced research progress in this sector. Moreover, FDA is developing new regulatory strategies regarding NGS, which is anticipated to boost innovation in tests, while ensuring that the data produced by these tests are accurate and reliable.
The increase in number of COVID-19 cases is expected to aid launch of new products under the EUA, aiding growth. In March 2020, first EUA was granted to BioFire Respiratory Panel 2.1, which was followed by other products like PerkinElmer SARS-CoV-2 RT-qPCR Reagent Kit and BD SARS-CoV-2/Flu. Multidrug Resistant (MDR) bacteria are associated with nosocomial infections and are a threat to public health.
U.S. Infectious Disease Molecular Diagnostics Market Product Outlook (Revenue, USD Million , 2018-2030)
Instruments Product
Reagents Product
Services Product
U.S. Infectious Disease Molecular Diagnostics Market Test location Outlook (Revenue, USD Million , 2018-2030)
Hospitals
Clinics
Diagnostics Laboratories
Research Institutes
U.S. Infectious Disease Molecular Diagnostics Market Technology Outlook (Revenue, USD Million , 2018-2030)
U.S. Infectious Disease Molecular Diagnostics Market Application Outlook (Revenue, USD Million , 2018-2030)
Respiratory Diseases
Tuberculosis
Meningitis
Gastrointestinal Tract Infections
HPV
Sexually Transmitted Infection
Sepsis
Drug Resistance Disease
Others Application
Reasons to subscribe to Infectious Disease Molecular Diagnostics Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Infectious Disease Molecular Diagnostics Market Outlook databook
Our clientele includes a mix of Infectious Disease Molecular Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Infectious Disease Molecular Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Infectious Disease Molecular Diagnostics Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
U.S. Infectious Disease Molecular Diagnostics Market, 2018-2030 (US$M)